Antibodies specific for type II mutant EGTR
AssigneesThe Johns Hopkins University, Duke University
InventorsBert Vogelstein, Darell Bigner
Life of this patent
Estimating the term…
Abstract
Polyclonal and monoclonal antibodies which recognize mutant epidermal growth factor receptors (EGFR) have been produced. The EGFR gene is amplified in 40% of malignant gliomas and frequently the amplified genes are rearranged. Internal deletions in four glioma cell lines created an epitope which was not present in normal EGFR. These mutant were characterized as expressing mutant type 1I EGFR and were found in a small percent of gliomas. Antibodies against these epitopes are useful for diagnosis of specific gliomas which express mutant type 1I EGFR.
Claims3
An isolated antibody which binds specifically to an EGFR mutant type II as represented by FIG. 2, but which does not bind specifically to EGFR found on normal cells expressing EGFR.
Dependencies are inferred from the claim text.